Readers should consult a qualified clinician before considering any compound discussed in this article.
With the UK's imminent launch of an oral Wegovy formulation, attention has turned to a side effect that patient forums have flagged for months: a transient mental cloudiness that some users describe as 'brain fog'.
This phenomenon, while not yet systematically characterized in large trials, appears in anecdotal reports and a handful of small observational studies. A 2023 preprint posted on Research Square (not yet peer reviewed) surveyed 120 semaglutide users and found that something like 30-40% reported subjective cognitive slowing during the first eight weeks of treatment. The mechanism remains unclear, though researchers have proposed that rapid shifts in glucose availability and altered insulin signalling in the brain may play a role.
Against this backdrop, a synthetic peptide called Selank has drawn interest from a small community of nootropic researchers. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is a heptapeptide analogue of the endogenous immunomodulator tuftsin. Its nootropic profile, explored primarily in rodent models and a limited number of human studies from the 2000s and 2010s, suggests anxiolytic and cognitive-enhancing properties without the sedation seen with classical benzodiazepines.
A 2019 review published in Current Pharmaceutical Design by Zozulya and colleagues collated findings from a dozen preclinical studies and noted that Selank appears to modulate the expression of brain-derived neurotrophic factor (BDNF) and influence monoaminergic systems. These are pathways that intersect with the metabolic and neurotrophic changes triggered by GLP-1 receptor agonists. The hypothesis, still speculative, is that Selank might buffer the cognitive side effects of rapid weight loss by stabilizing neurotrophic support during a period of metabolic flux.
Another compound that surfaces in these discussions is P21, a small peptide derived from the neurotrophic factor CNTF. P21 has been studied for its potential to enhance cognitive resilience during rapid weight loss, with some researchers positing that it may promote hippocampal neurogenesis. A 2022 paper in Behavioural Brain Research by Li and colleagues (awaiting replication) reported that P21 administration in mice on a calorie-restricted diet preserved performance on a Morris water maze task, while untreated mice showed deficits. The parallels to GLP-1-induced weight loss are indirect but intriguing.
Selank's cognitive effects under semaglutide have been explored in a small number of observational reports, though these lack the rigour of controlled trials. One frequently cited pilot study from 2018, conducted by a Moscow-based research group and published in the Russian Journal of Physiology, administered Selank intranasally at doses in the neighbourhood of 200-300 mcg to 15 healthy volunteers undergoing a fasting protocol. The authors noted a modest improvement in attention and working memory scores, but the sample size and lack of blinding limit any firm conclusions.
The BDNF-mediated mechanisms of P21 have been further detailed in recent work, which may offer a framework for understanding how peptides like Selank could interact with GLP-1 pathways. GLP-1 receptors are expressed in the hippocampus and prefrontal cortex, and their activation has been linked to both neuroprotection and, paradoxically, transient cognitive dulling in some contexts. A 2021 review in Frontiers in Neuroscience by Hamilton and colleagues speculated that the brain's adaptation to altered energy homeostasis might temporarily downregulate certain synaptic processes, and that exogenous neurotrophic support could theoretically smooth this transition.
Other compounds occasionally mentioned in the same breath include Cerebrolysin, a porcine brain-derived peptide mixture with a longer history of use in post-stroke recovery, and MOTS-c, a mitochondrial-derived peptide that has shown cognitive benefits in mouse models of aging. Pinealon, a short tripeptide, and NAD+ precursors are also sometimes discussed for their purported effects on neuronal metabolism. However, none of these have been specifically studied in the context of GLP-1 therapy, and the evidence for each remains at the level of small pilot studies or preclinical work.
The limitations of the current evidence base are substantial. Most data on Selank come from Russian-language journals and have not been independently replicated in Western laboratories. The dosing protocols vary widely, and the long-term safety of chronic peptide administration is unknown. For P21, the leap from rodent cognition to human brain fog is a large one, and no human trials have been registered. The 2022 review by Chang and colleagues in Peptides cautioned that while the theoretical rationale for combining neurotrophic peptides with metabolic therapies is plausible, "the translational gap remains wide and fraught with unknowns."
Open questions abound. Would Selank's anxiolytic effects confound the measurement of cognitive improvement? Does intranasal delivery achieve sufficient brain concentrations to modulate BDNF in relevant regions? Could chronic use downregulate endogenous neurotrophic signalling? And crucially, does the subjective experience of brain fog during GLP-1 therapy correlate with any objective cognitive deficit, or is it a benign epiphenomenon of weight loss? None of these have been answered.
Selank's role in cognitive preservation during GLP-1 protocols remains an open research question, not a settled strategy. For now, the conversation lives on preprint servers and in niche forums, where anecdote often outpaces evidence. Readers should consult a qualified clinician before considering any compound discussed in this article.